Nanexa
Swedish specialty pharma company developing long-acting injectable drug products using its proprietary PharmaShell® drug-delivery technology.
Last updated October 14, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Nanexa is a Swedish specialty pharmaceutical company focused on the development of long-acting injectable (LAI) drug products. The company is built around its proprietary drug-delivery platform, PharmaShell®, a silica-based nanoparticle coating technology that enables controlled, sustained release of active pharmaceutical ingredients over extended periods from a single injection. Nanexa's business model combines internal product development with partnerships and licensing agreements with larger pharmaceutical companies, allowing it to apply PharmaShell® to a range of drug candidates and therapeutic areas. The company was founded in 2007 and is headquartered in Uppsala, Sweden, a hub for life-science and pharmaceutical research. Nanexa is listed on the Nasdaq First North Growth Market in Stockholm. Its pipeline and partnered programs have focused on areas such as oncology, diabetes, and other chronic conditions where long-acting formulations can improve patient adherence and outcomes. Nanexa positions itself as a technology platform company rather than a traditional pharmaceutical manufacturer, seeking to out-license or co-develop its formulations with pharmaceutical partners. This positioning places it within the specialty pharma and drug-delivery segment of the healthcare industry, where proprietary formulation technologies are a key source of competitive advantage.
History
Nanexa was founded in 2007 in Sweden and has since developed into a specialty pharmaceutical company centered on its proprietary drug-delivery technology, PharmaShell®. The company is headquartered in Uppsala, one of Sweden's principal life-science clusters, which provides access to research infrastructure, talent, and potential partners. Nanexa's core innovation, PharmaShell®, is a silica-based nanoparticle coating that can be applied to active pharmaceutical ingredients to control their release profile. This technology is designed to enable long-acting injectable formulations, which can reduce dosing frequency and improve patient convenience and adherence compared with conventional immediate-release products. Over the years, Nanexa has pursued a strategy of combining internal development with external partnerships. By collaborating with larger pharmaceutical companies, Nanexa seeks to apply PharmaShell® to a variety of drug candidates and therapeutic areas, generating value through licensing, milestone payments, and royalties. The company has been listed on the Nasdaq First North Growth Market in Stockholm, giving it access to public capital to fund its research and development activities. As a technology platform company, Nanexa's progress is closely tied to the success of its partnered programs and the broader adoption of long-acting injectable formulations in the pharmaceutical market. The company continues to operate as an active specialty pharma developer in Sweden.
- 2007
Nanexa founded in Sweden.
Listed on Nasdaq First North Growth Market in Stockholm.
Products and positioning
Specialty pharma technology platform company focused on long-acting injectables and drug-delivery partnerships.
PharmaShell®
Proprietary silica-based nanoparticle drug-delivery platform enabling long-acting injectable formulations.
Recent events
- Unconfirmed
Novo Nordisk enters €1.17 billion deal with Nanexa for injection technology[2]
Reported:
Novo Nordisk entered a €1.17 billion deal with Nanexa covering injection technology, and Nanexa's shares soared on the news.
Nanexa signs $1.33 billion global licensing deal with Novo Nordisk for PharmaShell technology[3]
Reported:
Swedish drug-delivery company Nanexa announced a global licensing agreement with Novo Nordisk, granting the maker of Wegovy and Ozempic exclusive rights for up to five development programs to use Nanexa's PharmaShell technology, an ultra-thin inorganic coating on drug particles that controls release over time, for long-acting injectable drugs targeting obesity, type 2 diabetes and other cardiometabolic conditions. Nanexa is eligible for an upfront payment of around $700 million, milestone payments for development and regulatory achievements, and low single-digit royalties on future product sales, in a deal reported at $1.33 billion. Nanexa shares surged more than 150% at Friday's open in Stockholm before paring gains.
Weekdays and relative dates follow the original report; their exact calendar dates have not been verified.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/nanexa · Editorial policy · How profiles are compiled